Targeting HDAC Complexes in Asthma and COPD
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 1×
“A more novel but related approach is to target enzymes for degradation using the proteolysis targeting chimera (PROTAC) technique [177].”
MethodHDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 1×
“Tubulin is a major component of the cytoskeleton and is thereby involved in cell motility [85,86].”
BackgroundHistone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241 · cited 1×
“As an important example, acetylation of histones facilitates transcriptional activation either by neutralizing the ionic interaction between DNA and the histones or by forming a binding site for chromatin remodeling proteins and transcription factors [9,10].”
BackgroundApoptotic cell clearance: basic biology and therapeutic potential
Poon, I. K. H., Lucas, C. D., Rossi, A. G., & Ravichandran, K. S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3607 · Cited by 1,223 · cited 2×
“Increased apoptosis of eosinophils and neutrophils without their ti ely clearance by macrophages will result in disintegration of the apoptotic cells, causing damage to lung issue and propagation of the inflammatory response [96].”
BackgroundZhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103 · cited 1×
“Additionally, two copies of the methyl binding domain proteins MBD2/3 can join in to mediate the association with MTA1/2/3 and modify deacetylase activity [130].”
BackgroundLessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · cited 2×
“This may be the result of the formation of a stable ternary complex between the E3 ligase and HDAC6 and not with the other HDACs [182], but further research is needed to confirm this.”
BackgroundFischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754 · cited 1×
“The exact role of these class IIa HDACs in this complex has not been determined yet, although HDAC3 is likely to be the sole enzymatic subunit responsible for deacetylase activity, since the other HDACs do not possess catalytic activity of their own [159,160].”
BackgroundHDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 1×
“Tubulin is a major component of the cytoskeleton and is thereby involved in cell motility [85,86].”
BackgroundChemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., & Adcock, I. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050466 · Cited by 638
The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3
Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706487104 · Cited by 566 · cited 1×
“The exact role of these class IIa HDACs in this complex has not been determined yet, although HDAC3 is likely to be the sole enzymatic subunit responsible for deacetylase activity, since the other HDACs do not possess catalytic activity of their own [159,160].”
BackgroundRajendrasozhan, S., Yang, S.-R., Kinnula, V. L., & Rahman, I. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1269oc · Cited by 520 · cited 1×
“Additionally, HDAC5 and 8 were expressed to a lesser extent, SIRT1 activity is decreased, HDAC1, 3, 4, 6 and 7 expression levels were unchanged and the expression and activity of HDAC9, 10, 11 and the other sirtuins is unknown [49,50].”
BackgroundStructure of Hdac3 Bound to Co-Repressor and Inositol Tetraphosphate
Watson, P. J., Fairall, L., Santos, G. M., & Schwabe, J. W. R. (2012) · Nature · doi:10.1038/nature10728 · Cited by 505 · cited 1×
“Co-repressor proteins and HDAC enzymes are simultaneously in contact with InsP and InsP can thus be viewed as a form of molecular glue, bonding the complex together [133,172,173].”
BackgroundCoREST: A functional corepressor required for regulation of neural-specific gene expression
Andrés, M. E., Burger, C., Peral-Rubio, M. J., Battaglioli, E., Anderson, M. E., Grimes, J., Dallman, J., Ballas, N., & Mandel, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9873 · Cited by 494
A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness
Guenther, M. G., Lane, W. S., Fischle, W., Verdin, E., Lazar, M. A., & Shiekhattar, R. (2000) · Genes & Development · doi:10.1101/gad.14.9.1048 · Cited by 489
Webster, J. C., Oakley, R. H., Jewell, C. M., & Cidlowski, J. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121455098 · Cited by 482
Zhang, J., Kalkum, M., Chait, B. T., & Roeder, R. G. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00468-9 · Cited by 414
Chen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397 · cited 2×
“This is further supported by the finding that HDAC3-deficient macrophages induce only half of the genes linked to LPS-induced inflammatory gene expression [72].”
BackgroundResultNucleosome Remodeling and Epigenetics
Becker, P. B., & Workman, J. L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a017905 · Cited by 355
Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation
Mullican, S. E., Gaddis, C. A., Alenghat, T., Nair, M. G., Giacomin, P. R., Everett, L. J., Feng, D., Steger, D. J., Schug, J., Artis, D., et al. (2011) · Genes & Development · doi:10.1101/gad.175950.111 · Cited by 314 · cited 1×
“The HDAC3/SMRT/NCoR complex has been shown to suppress the IL-4-activated alternative pathway and is thereby believed to act as a brake for alternative activation [165].”
BackgroundHistone deacetylase 6–mediated selective autophagy regulates COPD-associated cilia dysfunction
Lam, H. C., Cloonan, S. M., Bhashyam, A. R., Haspel, J. A., Singh, A., Sathirapongsasuti, J. F., Cervo, M., Yao, H., Chung, A. L., Mizumura, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69636 · Cited by 307
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions
Tran, A. D.-A., Marmo, T. P., Salam, A. A., Che, S., Finkelstein, E., Kabarriti, R., Xenias, H. S., Mazitschek, R., Hubbert, C., Kawaguchi, Y., et al. (2007) · Journal of Cell Science · doi:10.1242/jcs.03431 · Cited by 281 · cited 1×
“Fibroblasts also have reduced motility upon inhibition of HDAC6 [87,88].”
BackgroundHistone deacetylases: transcriptional repression with SINers and NuRDs
Ayer, D. E. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01536-6 · Cited by 274 · cited 1×
“The structures of HDAC1 and HDAC2 are very similar, and as such, are recruited interchangeably towards the same complexes [110].”
BackgroundInsights into the activation mechanism of class I HDAC complexes by inositol phosphates
Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., Cowley, S. M., Jamieson, A. G., Potter, B. V. L., & Schwabe, J. W. R. (2016) · Nature Communications · doi:10.1038/ncomms11262 · Cited by 244 · cited 1×
“Co-repressor proteins and HDAC enzymes are simultaneously in contact with InsP and InsP can thus be viewed as a form of molecular glue, bonding the complex together [133,172,173].”
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191 · cited 7×
“Other investigations confirmed that aromatic groups in the 4 position, such as 2-thienyl (compound 7) [104], 2-furyl (compound 8) [108], 3-furyl (compound 9) [108] and 4-pyrimidinyl (compound 10) [103], result”
BackgroundMethodInfluentialThe nucleosome remodeling and deacetylase complex in development and disease
Basta, J., & Rauchman, M. (2015) · Translational Research · doi:10.1016/j.trsl.2014.05.003 · Cited by 191 · cited 1×
“Overall, NuRD is regarded as an important mediator during the developmental stages of life, playing important roles in cell cycle progression, DNA repair and chromatin remodeling [136].”
BackgroundDevelopment of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180 · cited 1×
“Also, novel examples will be given regarding drugs developed to specifically target these complexes since the most recent review [115].”
BackgroundGnanapragasam, M. N., Scarsdale, J. N., Amaya, M. L., Webb, H. D., Desai, M. A., Walavalkar, N. M., Wang, S. Z., Zu Zhu, S., Ginder, G. D., & Williams, D. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015341108 · Cited by 148 · cited 1×
“The nuclear zinc-finger transcriptional repressor p66-α (GATAD2A) and p66-β (GATAD2B) also directly interact with MBD proteins [131].”
BackgroundLeus, N. G. J., van der Wouden, P. E., van den Bosch, T., Hooghiemstra, W. T. R., Ourailidou, M. E., Kistemaker, L. E. M., Bischoff, R., Gosens, R., Haisma, H. J., & Dekker, F. J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.03.010 · Cited by 131 · cited 2×
“In support of this, selective inhibition of HDAC3 with the inhibitor RGFP966 in LPS/IFN-γ stimulated macrophages attenuated the NF-kB transcriptional activity and demonstrated anti-inflammatory effects [81].”
BackgroundSelf-citationMarek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 122 · cited 1×
“The selectivity difference between these hydroxamic acid HDACi is poorly understood but is under active investigation [99].”
BackgroundBlank, M. F., & Grummt, I. (2017) · Transcription · doi:10.1080/21541264.2016.1276658 · Cited by 111 · cited 1×
“These HDACs are named sirtuins and can reside in the nucleus, mitochondria or cytoplasm, depending on the isoform [31].”
BackgroundOptimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, D. J., Harrington, P., Wilson, K. J., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., & Miller, T. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.047 · Cited by 93 · cited 1×
“Interestingly, aromatic substituents in position 4 lead to selective inhibition of HDAC1 and HDAC2 over HDAC3 [104,108,109].”
BackgroundWagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86 · cited 1×
“Replacing fluorine with a chlorine leads to a decrease in potency similar to replacement with the electron-donating methyl and methoxy groups [102,106].”
BackgroundTherapeutic effects of histone deacetylase inhibitors in a murine asthma model
Ren, Y., Su, X., Kong, L., Li, M., Zhao, X., Yu, N., & Kang, J. (2016) · Inflammation Research · doi:10.1007/s00011-016-0984-4 · Cited by 68
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, F., Zwinderman, M., & Dekker, F. (2018) · Molecules · doi:10.3390/molecules23030551 · Cited by 66 · cited 1×
“Class IIA HDACs include HDAC4, 5, 7, 9 and class IIB harbors HDAC6 and 10 and have mostly cytoplasmic functions [34,35].”
BackgroundSelf-citationBecher, I., Dittmann, A., Savitski, M. M., Hopf, C., Drewes, G., & Bantscheff, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500235n · Cited by 60 · cited 1×
“The Sin3/HDAC1/2 complex was shown not be targeted by these HDACi at all, which is largely due to thermodynamic rather than kinetic reasons [114].”
BackgroundKim, S.-H., Kim, D.-H., Lavender, P., Seo, J.-H., Kim, Y.-S., Park, J.-S., Kwak, S.-J., & Jee, Y.-K. (2009) · Experimental and Molecular Medicine · doi:10.3858/emm.2009.41.5.033 · Cited by 34
Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20 · cited 2×
“Interestingly, aromatic substituents in position 4 lead to selective inhibition of HDAC1 and HDAC2 over HDAC3 [104,108,109].”
Background
Cited by
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Overview of the Mechanisms of Oxidative Stress: Impact in Inflammation of the Airway Diseases
Albano, G. D., Gagliardo, R. P., Montalbano, A. M., & Profita, M. (2022) · Antioxidants · doi:10.3390/antiox11112237 · Cited by 256
Adhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Luo, Y., & Li, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228828 · Cited by 62
Metadata
- Authors
- Zwinderman, M. R. H., de Weerd, S., & Dekker, F. J.
- Venue
- Epigenomes
- Publisher
- MDPI AG
- Published
- 2019-09-07
- Volume
- 3
- Issue
- 3
- Pages
- 19
- ISSN
- 2075-4655 (ISSN-L)
- OpenAlex
- W2972274682
- Cited by
- 52
- References
- 40
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.